WAP
TEVA icon

Wealthcare Advisory Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Wealthcare Advisory Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4,966
Closed -$57K – 1733
2021
Q1 		$57K Buy
+4,966
New +$56.9K ﹤0.01% 839
2020
Q2 		– Sell
-1,242
Closed -$11K – 1242
2020
Q1 		$11K Buy
1,242
+1,125
+962% +$11.5K ﹤0.01% 908
2019
Q4 		$1K Sell
117
-184
-61% -$1.64K ﹤0.01% 1345
2019
Q3 		$2K Sell
301
-50
-14% -$383 ﹤0.01% 1241
2019
Q2 		$3K Sell
351
-50
-12% -$603 ﹤0.01% 1156
2019
Q1 		$6K Hold
401
– – ﹤0.01% 935
2018
Q4 		$6K Buy
401
+50
+14% +$1.02K ﹤0.01% 903
2018
Q3 		$8K Hold
351
– – ﹤0.01% 914
2018
Q2 		$9K Sell
351
-4,618
-93% -$94.2K ﹤0.01% 875
2018
Q1 		$85K Buy
4,969
+50
+1% +$976 0.02% 309
2017
Q4 		$93K Buy
4,919
+3,401
+224% +$51.2K 0.02% 271
2017
Q3 		$27K Buy
+1,518
New +$34.2K 0.01% 387

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Wealthcare Advisory Partners's TEVA Position: Q2 2021 in Review

Wealthcare Advisory Partners sold out of Teva Pharmaceuticals (TEVA) in Q2 2021, closing a stake of 4,966 shares — an estimated $57K sold.

Wealthcare Advisory Partners first reported a position in TEVA in Q3 2017 and held it in 12 quarters. The position peaked at $93K in Q4 2017. 440 funds tracked by Wall St. Rank hold TEVA as of Q2 2021.

  • Wealthcare Advisory Partners reported no remaining Teva Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Wealthcare Advisory Partners sold 4,966 Teva Pharmaceuticals shares in Q2 2021, an estimated $57K.
  • Wealthcare Advisory Partners first reported a position in Teva Pharmaceuticals in Q3 2017 and held it in 12 quarters.
  • Wealthcare Advisory Partners's Teva Pharmaceuticals position peaked at $93K in Q4 2017.
  • 440 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2021.

Based on Wealthcare Advisory Partners's 13F filing for Q2 2021, filed 16 Aug 2021.